CTLA4 and neoplasm: The combination with the vaccine is predicted to improve the efficacy of the mono-therapy, since the corresponding optimal protocol provides a faster tumor reduction, while administering a lower amount of anti-CTLA4, with a consequent reduction in ipilimumab-related toxicity.